The vaccine approval process is a complex and highly regulated pathway designed to ensure that vaccines are safe, effective, and of high quality before they are made available to the public. Regulatory authorities such as the United States Food and Drug Administration (FDA), European Medicines Agency (EMA), and India’s Central Drugs Standard Control Organization (CDSCO) oversee the process, with the primary goal of protecting public health while enabling timely access to critical vaccines. The approval process can be broadly divided into preclinical evaluation, clinical trials, regulatory submission, and post-marketing surveillance, each stage having specific requirements and regulatory scrutiny. The first stage in vaccine development is the preclinical phase, which involves laboratory and animal studies. During this phase, researchers study the vaccine candidate’s biological properties, mechanism of action, immunogenicity, and potential toxicity. Preclinical studies are essential to identify the initial safety profile, appropriate dosing, and immune responses elicited by the vaccine. Regulatory authorities require detailed documentation of these studies in the form of an Investigational New Drug (IND) application or equivalent, which must be submitted before human trials can begin. The preclinical data serves as the foundation for moving into clinical trials and is critical for demonstrating that the vaccine is reasonably safe to test in humans. Once preclinical studies show promising results, the vaccine enters clinical trials, which are typically conducted in three phases. Phase I trials involve a small group of healthy volunteers, often between 20 and 100 individuals, and focus primarily on safety and tolerability. This phase evaluates potential adverse effects, immune responses, and appropriate dosing ranges. Phase I trials also help refine the administration route, whether intramuscular, subcutaneous, or oral. Close monitoring is essential during this phase, as any unexpected adverse reactions can halt the study or lead to modifications in the formulation. Phase II trials expand the study to several hundred participants and aim to further assess safety, optimal dosing, and preliminary efficacy. This phase often includes diverse populations to better understand how the